Publicacións en colaboración con investigadores/as de Hospital of the University of Pennsylvania (15)

2024

  1. Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting

    Clinical Lymphoma, Myeloma and Leukemia

  2. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202

2023

  1. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

    Blood, Vol. 141, Núm. 3, pp. 219-230

2022

  1. Teclistamab in Relapsed or Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 387, Núm. 6, pp. 495-505

2021

  1. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

    The Lancet, Vol. 398, Núm. 10301, pp. 665-674

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2015

  1. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

    Biology of Blood and Marrow Transplantation, Vol. 21, Núm. 12, pp. 2039-2051

2011

  1. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, Núm. 1, pp. 38-43

2009

  1. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)

    Leukemia, Vol. 23, Núm. 10, pp. 1904-1912

  2. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma

    European Journal of Haematology, Vol. 82, Núm. 6, pp. 426-432

  3. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

    Blood, Vol. 114, Núm. 9, pp. 1729-1735

  4. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline

    British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903

2008

  1. Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study

    Leukemia, Vol. 22, Núm. 4, pp. 842-849

2007

  1. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

    British Journal of Haematology, Vol. 137, Núm. 5, pp. 429-435

2005

  1. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498